Alpha lactalbumin is a whey protein, found among other places, in mothers milk. It has recently been in the news as the primary protein used in the search for a cure for breast cancer.

For the last eight years, Dr. Vincent Tuohy, at the Cleveland Clinic, has been searching for a vacine for breast cancer. Dr. Tuohy discovered that mice injected with the vaccine, based on Alpha lactalbumin, did not develop breast tumors, while 100 percent of the mice that were not vacinated, had breast tumors.

The vacine also seems to inhibit the growth of pre-existing tumors.

In an interview he also states that "There's nothing fancy about it. We're vaccinating against something that isn't there unless you have tumors, so it shouldn't harm you. And it should kill the tumors,".

The main part of the vaccine, a protein called Alpha lactalbumin found in lactating breasts, is also found in breast tumors, but not in healthy breasts. It is suggested that women who are finished breast feeding, would recieve the vaccine thus boosting their own immune systems and supplying the means to kill off cancerous cells while not damaging healthy ones.

"We think that breast cancer is a completely preventable disease in the same way that polio is completely preventable," Dr. Tuohy says.

This sort of research gives hope to anyone who has, or knows of anyone with breast cancer. To say nothing of outright prevention. In 2009, The American cancer society estimates that there was 192,370 new cases of invasive breast cancer and 40,170 deaths from breast cancer.

(c) 2010 Alphalactalbumin.com

Use of this article is forbidden without express permission from the author.

Susan G. Komen , the Young Survival Coalition and Living Beyond Breast Cancer Applaud Bill to Reauthorize the Breast ...
Susan G. Komen, the Young Survival Coalition and Living Beyond Breast Cancer today applauded a new bill to reauthorize the Breast Health Education and Awareness RequirRead More...

Long-Shot Breast Cancer Drug Now Promises Fortune, but Not for Big Pharma
Alan Auerbach specializes in testing drugs that Big Pharma doesn't want anymore, and that has made him a billionaire. In 2011, the Puma Biotechnology Inc. chief executive officer leveraged the industry connections he gained from his past at a previous company to license an obscure breast cancer drug from Pfizer Inc. Now his latest company may have a bestseller, thanks to a trial Pfizer started ...Read More...

Breast cancer drugs 'impaired by street lights'
Researchers find that lights could make certain cancers resistant to the drug tamoxifenRead More...

Ivory Latta, following cancer scare, is grateful for time with Washington Mystics
Sunday s breast cancer awareness game has special meaning this year for Mystics guard Ivory Latta.Read More...

'Revolutionary' new cancer therapy
Tens of thousands of breast cancer sufferers could benefit from an "innovative" new type of radiotherapy which could be delivered during surgery instead of making them take a course of treatment.Read More...

Half-hour breast cancer treatment can replace weeks of radiotherapy: Thousands of women could benefit from treatment ...
The intrabeam radiotherapy treatment, which is delivered during surgery under anaesthetic, has been given the provisional go-ahead for use on the NHS.Read More...

Breast cancer patients to get new quick radiotherapy treatment
Breast cancer patients will be given a 20-minute one off dose of radiotherapy during surgery to remove their tumour instead of repeated visits afterwards, following approval by NiceRead More...

Breast Cancer Survivor's Breast Implant Explodes During Surgery Watch the Insane Botched Clip!
On this Sunday's Botched, we meet a breast cancer survivor named Cynthia, whose previous single mastectomy and reconstruction went completely wrong. While she only has one botched...Read More...

One-shot cancer therapy gets NHS nod
A pioneering breast cancer treatment that replaces weeks of radiotherapy with a single, targeted shot is set to be offered on the NHS.Read More...

Puma says cancer drug meets trial goal, shares soar
(Reuters) - Puma Biotechnology Inc said its experimental breast cancer drug met its main goal in a late-stage trial. Puma said on Tuesday it plans to file for marketing approval of neratinib, code named PB272, in the first half of 2015. Adjuvant treatment with the drug showed a statistically significant improvement in disease-free survival of 33 percent versus patients on placebo, according to ...Read More...